4.4 Article

American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Journal

ARTHRITIS CARE & RESEARCH
Volume 64, Issue 6, Pages 797-808

Publisher

WILEY
DOI: 10.1002/acr.21664

Keywords

-

Categories

Funding

  1. UCB
  2. Abbott
  3. HGS/GSK
  4. Amgen
  5. Pfizer
  6. Lilly
  7. Bristol-Myers Squibb
  8. Genentech/Roche
  9. EMD Serono
  10. Neovacs
  11. Cephalon
  12. MedImmune
  13. Questcor
  14. Argos
  15. Ono
  16. Astellas
  17. Baxter
  18. RPS
  19. Takeda
  20. Human Genome Sciences/GlaxoSmithKline
  21. Parexel
  22. ViiV
  23. Novartis
  24. Genzyme
  25. Cubist

Ask authors/readers for more resources

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. The American College of Rheumatology is an independent, professional, medical and scientific society which does not guarantee, warrant, or endorse any commercial product or service.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available